Oral semaglutide shows promising results for type 2 diabetes in routine clinical settings

FHS
May 28, 2024
1:27 pm

Semaglutide and its effects on glycemic control, body weight (BW), and tolerability in routine clinical practice.

Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology | Psychedelic Invest

SARASOTA, FL, Feb. 01, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing

February 2, 2024

Sionna licenses clinical-stage cystic fibrosis assets from AbbVie shortly after large Series C

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 17, 2024

Mahvash Disease Case Resolved With Liver Transplantation

A woman with Mahvash disease presented with portal hypertension that necessitated liver transplantation; the liver complications observed in this case report distinguish it from what’s

November 23, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.